1Life Healthcare jumps after William Blair sees vaccine rollout benefits

William Blair analyst Ryan Daniels sees 1Life Healthcare as a potential derivative beneficiary from the administration of Covid-19 vaccines. The company's support for vaccines in New York, Seattle and the San Francisco area, coupled with its plans to provide complimentary services to qualifying patients, could increase sales from vaccinations and "serve as a bit of a Trojan-horse marketing campaign to acquire new members," Daniels told investors earlier in a research note. The analyst keeps an Outperform rating on the shares. 1Life Healthcare in early trading is 9%, or $4.51, to $52.22.